Karuna Therapeutics, Inc.
Net SellingKRTX·US·🇺🇸 US
20%buys·80%sales
949 transactions$73.0MTotal buys·49 buys
$609.0MTotal sells·194 sells
2828 insiders
Last: Mar 18, 2024
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Mar 18, 24 | Brannan Stephen K. | Disposition | $3.4M | |
| Mar 18, 24 | Brannan Stephen K. | Disposition | $1.5M | |
| Mar 18, 24 | Brannan Stephen K. | Disposition | $2.0M | |
| Mar 18, 24 | Brannan Stephen K. | Disposition | $11.5M | |
| Mar 18, 24 | Brannan Stephen K. | Disposition | $2.5M | |
| Mar 18, 24 | Brannan Stephen K. | Disposition | $8.2M | |
| Mar 18, 24 | Brannan Stephen K. | Disposition | $2.5M | |
| Mar 18, 24 | Brown Jason Parker | Disposition | $1.2M | |
| Mar 18, 24 | Brown Jason Parker | Disposition | $981K | |
| Mar 18, 24 | Brown Jason Parker | Disposition | $2.2M |
Karuna Therapeutics, Inc. (KRTX) has recorded 949 insider transactions from 28 insiders. Total insider buying volume stands at $73.0M, while total selling volume is $609.0M. Overall insider sentiment is bearish (80% sales).
Karuna Therapeutics, Inc. (KRTX) has recorded 949 insider operations, including 49 open-market purchases ($73.0M), 194 sales ($609.0M) and 706 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (80% sales).
Insider activity at Karuna Therapeutics, Inc. is sustained, with operations recorded in 12 of the last 12 months — a sign of regular regulatory filings.
Among the most active insiders are PAUL STEVEN M (CEO), Meury William (CEO) & Ignelzi Troy A. (CFO), with respectively 211, 198, 138 transactions.
Across all 949 recorded transactions, the breakdown by type is: exercise (406, 43%), sales (194, 20%), other (100, 11%), disposition (95, 10%), grant (84, 9%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Karuna Therapeutics, Inc. has recorded 949 insider operations in total, including 49 open-market purchases ($73.0M), 194 sales ($609.0M) and 706 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on March 18, 2024.
Insiders at Karuna Therapeutics, Inc. are currently net sellers, with 20% purchases and 80% sales across all reported transactions. Total buy volume is $73.0M versus $609.0M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 28 insiders at Karuna Therapeutics, Inc. (KRTX). PAUL STEVEN M (CEO, 211 tx), Meury William (CEO, 198 tx), Ignelzi Troy A. (CFO, 138 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for KRTX is bearish, based on a 20% buy ratio across 243 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Karuna Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.